2008-08-15 22:33:01 -

www.amriglobal.com - AMRI (NASDAQ: AMRI) today announced that Thomas E. D'Ambra, Ph.D., chairman, chief executive officer and president, after consulting with the company's board of directors, has adopted a pre-arranged stock trading plan to sell a fraction of shares of the company in an orderly manner. The shares to be sold are jointly owned by Dr. and Mrs. D'Ambra. Dr. D'Ambra's plan was adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Effective August 11, 2008, the plan allows for the sale of up to 500,000 shares, subject to satisfaction of certain conditions through July 31, 2009. The 500,000 shares available for sale under the plan represent approximately 10.8% of the total number of shares

of common stock jointly held by Dr. and Mrs. D'Ambra (excluding the 3,065,189 shares held in the Thomas E. D'Ambra Family Trust I of which Dr. and Mrs. D'Ambra have disclaimed ownership). The planned sales are intended to diversify holdings and for estate planning purposes. All transactions under the plan will be disclosed through Form 144 and Form 4 filings with the Securities and Exchange Commission as required by applicable securities laws.

Under the terms of the plan, sales may commence in approximately 60 days. Subject to certain share price and other parameters, no more than 100,000 shares will be sold in any given month during the plan.

Rule 10b5-1 permits corporate officers, directors and others to adopt written, pre-arranged stock trading plans when they are not in possession of material, non-public information. Using these plans, insiders may gradually diversify their investment portfolios and spread stock trades over a period of time regardless of any material, non-public information they may receive after adopting their plans. In accordance with 10b5-1 rules, Dr. and Mrs. D'Ambra will have no discretion over sales under his plan.

About AMRI

Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.

AMRI
Media - Andrea Schulz, 518-512-2226
Corporate Communications
or
Investors - Peter Jerome, 518-512-2220
Director of Investor Relations